# Non-Inferiority Study on MRNA-lncRNA Model in Low-Risk Triple-Negative Breast Cancer Patients

Source: https://onco.cc/trials/nct06795503/  
OnCo record `nct06795503` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of docetaxel, cyclophosphamide, epirubicin and paclitaxel / nab-paclitaxel in triple-negative breast cancer, run by Fudan University, not yet recruiting.

## Summary

Non-Inferiority Study on MRNA-lncRNA Model in Low-Risk Triple-Negative Breast Cancer Patients is a phase 3, randomised interventional study registered as NCT06795503 by Fudan University, with a registry enrolment figure of 1462 participants, started 2025-02 and due to reach its primary completion in 2028-08. Interventions recorded: Docetaxel plus cyclophosphamide; Epirubicin, cyclophosphamide plus paclitaxel. Conditions listed: Triple-negative Breast Cancer. Triple-negative eligibility wording from the registry: "Histologically confirmed invasive triple-negative breast cancer (TNBC), defined as breast cancer with estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) all determined to be negative by pathological testing". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT06795503
- Phase: 3
- Setting: Non-Inferiority Study on MRNA-lncRNA Model in Low-Risk Triple-Negative Breast Cancer Patients
- Sponsor: Fudan University
- Enrolled: 1462

## Sources

- ClinicalTrials.gov NCT06795503: https://clinicaltrials.gov/study/NCT06795503

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- drugs: [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/), [Docetaxel](https://onco.cc/drugs/docetaxel/), [Epirubicin](https://onco.cc/drugs/epirubicin/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06795503.json